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Summary
Objective: The growth-arrest-speciﬁc protein, Gas7, has been shown to be involved in reorganization of the cytoskeleton and for inducing
changes in cell shape during cell differentiation. The goals of this study were to investigate the novel role of human Gas7 (hGas7) in
chondrogenic differentiation of human mesenchymal stem cells (hMSCs) and to identify the relationship between hGas7, extracellular
signal-regulated kinase (ERK1/2) and SOX9 in the chondrogenic pathway.
Methods: Bone marrow-derived hMSCs were induced to undergo chondrogenic differentiation with transforming growth factor-b1 (TGF-b1) in
an aggregate culture system. The expression of hGas7 and SOX9 and phosphorylation of ERK1/2 at multiple time points were investigated.
Chondrogenic capacity was evaluated by the size of aggregates, by glycosaminoglycan content, and by type II collagen and proteoglycan
deposition after interfering with expression of hGas7, ERK1/2 or SOX9. To delineate the functional role of these genes in chondrogenesis,
inhibition of individual gene’s expression in hMSCs, by antisense oligonucleotides or interference RNA (siRNA), and the effect on chondro-
genic differentiation were also investigated.
Results: Treatment of hMSCs with TGF-b1 resulted in a transient up-regulation of hGas7b, one of the hGas7 isoforms (day 3eday 5), a tran-
sient phosphorylation of ERK1/2 (0.5e4 h) and an up-regulation of SOX9 (2 h to day 14). Transient expression of hGas7b was also detected in
hMSCs by reverse transcription-polymerase chain reaction at day 2 and day 3 following TGF-b1 treatment. Interference with hGas7b produc-
tion by hGas7b-speciﬁc antisense oligonucleotide or inhibition of p-ERK with PD98059, a speciﬁc inhibitor of ERK signaling pathway, or
interference with SOX9 production by SOX9 siRNA all caused adverse effects of chondrogenic differentiation of hMSCs. Meanwhile, inhibition
of p-ERK or SOX9 both blocked the expression of hGas7b. However, the p-ERK and SOX9 pathway was not affected by inhibition of hGas7b.
Conclusion: These results provide evidence that the transient expression of hGas7b, regulated by activation of ERK1/2 and SOX9 pathway, is
essential for chondrogenic differentiation of hMSCs.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
During normal tissue development, arrest of cell growth
precedes differentiation1. Growth-arrest-speciﬁc (Gas) pro-
teins, whose expression is associated with cell quiescence,
have varied biological functions including the control of
cytoskeleton organization2,3, cell differentiation4,5, apopto-
sis6, tyrosine kinase receptor activity7, and the negative8
and positive7 control of cell cycling.
Gas7 is expressed predominantly in adult mouse brain
and testis and is essential for neurite outgrowth in cultured
cerebellar neurons9. Regulated expression of Gas7 may be
important for the development of other tissues as well, as
suggested by the detection of an mixed lineage leukemia
(MLL)eGas7 translocation in individuals with treatment-*Address correspondence and reprint requests to: Dr Chuck
C.-K. Chao, Ph.D., Department of Biochemistry and Molecular
Biology, Chang Gung University, Taoyuan 333, Taiwan. Tel: 886-
3-2118800ext.5157; Fax: 886-3-2118700; E-mail: cckchao@
mail.cgu.edu.tw
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1403related acute myeloid leukemia (AML) . Two different hu-
man Gas7 (hGas7) isoforms, hGas7a with 2427 nucleo-
tides, which are corresponding to Gas7cb form in mice3
and encodes 330 amino acids, and hGas7b with 2610 nu-
cleotides, which encodes 412 amino acids, have been iden-
tiﬁed in multiple different human tissues11.
Human mesenchymal stem cells (hMSCs) are capable of
differentiation into several different lineages and have been
considered a candidate cell source for tissue engineering
and regenerative medicine12. Their multi-potential capacity
also makes them a useful model to investigate mechanisms
regulating tissue development and regeneration, such as
cartilage13. During hMSC chondrogenic differentiation, the
changes in cell morphology are very clear. The cells change
from the characteristic ﬁbroblast-like phenotype to large
round cells surrounded by abundant extracellular matrix.
Many of these changes can be understood in terms of
a dynamic reorganization of the cytoskeletal network. The
functional role of Gas7 in reorganization of actin can induce
changes in cell shape3. Based on these observations, Gas7
could be involved in chondrogenesis of hMSCs.
1404 Y. Chang et al.: Involvement of Gas7 in chondrogenesis of hMSCsCartilage formation is a complex process initiated by con-
densation of undifferentiated pre-chondrogenic cells and
followed by progression through chondrogenic differentia-
tion14,15. Several extracellular signaling ligands have been
implicated in the process of chondrogenic differentiation.
The extracellular signal-regulated kinase (ERK) has been
documented to be involved in chondrogenesis of several
different types of cells including ATDC516, chick mesen-
chyme17,18, C3H10T1/219, and hMSCs20. In addition,
SOX9, a member of the SOX (Sry-type HMG box) family,
regulates expression of the gene encoding type II collagen,
the major matrix of cartilage and enhances aggrecan gene
activity in chondrocytes. These observations indicated that
SOX9 plays a key role in chondrogenesis. The expression
of SOX9 can be activated by transforming growth factor-
b (TGF-b) family members through the mitogen-activated
protein (MAP) kinases’ pathway16,20.
Recent evidence has increasingly suggested that signal-
ing cascades and pathways act in an interconnected man-
ner within the cell. In this study, we attempt to deﬁne the
role of Gas7 in mesenchymal chondrogenesis, speciﬁcally
in bone marrow (BM)-derived hMSCs. We also investigated
the relationship between ERK1/2eSOX9 pathway and
Gas7 in the chondrogenesis of hMSCs.MethodsISOLATION AND CHONDROGENESIS OF hMSCsBM aspirates were obtained from the posterior iliac crest of patients
undergoing spinal surgery after informed consent obtained under the terms
of an Institutional Review Board-approved protocol. The procedures for
establishing hMSC cultures followed previously published methods21,22.
To isolate hMSCs, a 10 ml aliquot of BM aspirate was enriched for hMSCs
by density gradient centrifugation over a Percoll cushion (SigmaeAldrich,
St. Louis, MO, USA). The cells at the mediumePercoll interface were col-
lected, counted, and plated in 100 mm culture dishes at a density of
107 cells/dish and were cultured until near conﬂuence for further investiga-
tion. First passage cells were used to initiate this experiment.
Chondrogenesis of hMSCs was induced by culture in an aggregate culture
system23,24. In brief, cells were trypsinized, counted, and resuspended in in-
complete chondrogenic medium [Dulbecco’s modiﬁed eagle medium - high
glucose (DMEMeHG) supplemented with 1% ITSþPremix (BD, Franklin
Lakes, NJ, USA), 100 mM ascorbate-2-phosphate, 107 M dexamethasone,
0.1 mM non-essential amino acids (Gibco, Carlsbad, CA, USA), and 1 mM so-
dium pyruvate (Gibco)] at a density of 1.25 106 cells/ml. Cells (2.5 105)
cultured in incomplete chondrogenic medium with or without 10 ng/ml TGF-
b1 (R&D systems, Minneapolis, MN, USA) were seeded in polypropylene
96-well plates. Culture medium without TGF-b1 was unable to induce chon-
drogenesis of hMSCs in aggregate culture system (data not shown). Incom-
plete chondrogenic mediumþ 10 ng/ml TGF-b1 was also named as
complete chondrogenic medium in the following studies. Aggregates from
multiple different time points were processed for further investigation.INHIBITION OF hGas7First passage cells were seeded at a density of 3 104 cells/cm2 12 h
before transfection. hGas7 inhibition was mediated by transient transfection
with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). In preliminary
experiments, Lipofectamine 2000 did not exhibit adverse effects on chondro-
genic differentiation of hMSCs (data not shown). Dilution of 1.2 mg/ml phos-
phorothioated hGas7a antisense oligonucleotide (hGas7a-As nucleotide
sequence 50-ATTGGACATTTTTTC-30) or phosphorothioated hGas7b anti-
sense oligonucleotide (hGas7b-As nucleotide sequence 50-GGGGAC
CATTCCAGAC-30), both spanning the ATG start codon, and 1.8 ml/ml Lipo-
fectamine 2000 was carried out in serum-free medium. Control cultures
were treated with Lipofectamine 2000 alone. The transfection mixture that
had been added to the adherent hMSC was replaced after 24 h with culture
medium. After 12 h, the medium was removed from the cultures, the cell
layers were washed with phosphate-buffered saline (PBS), and the cells
were detached by incubation with 0.25% trypsin/ethylenediaminetetraacetic
acid (EDTA), counted, and induced to undergo chondrogenesis as described
above. Phosphorothioated hGas7 antisense oligonucleotide is expected to be
stable for at least 3 days, so in our experiments culture media were replaced
with fresh medium containing antisense oligonucleotides every 3 days.OVEREXPRESSION OF hGas7In brief, the hGas7aeenhanced green ﬂuorescent protein (EGFP) or
hGas7beEGFP fusion protein was expressed with the cytomegalovirus
(CMV) promoter and was constructed by ligation of polymerase chain reac-
tion (PCR)-ampliﬁed DNA containing full length hGas7a or hGas7b9 into the
vector. The resulting constructs were named hGas7aeEGFP or hGas7be
EGFP, respectively. Transient transfection was mediated by Lipofectamine
2000 as described above. To assess non-speciﬁc effects resulting from
the transfection process, itself, a similar GFP plasmid without the hGas7
cDNA sequence was also used. Determination of transfection efﬁciency
was performed 24 h after transfection by ﬂuorescence microscopy (Olympus,
Japan). For each experiment, at least three microscopic visual ﬁelds (100-
fold magniﬁcation) were counted, and the ratio of EGFP-expressing cells
to non-ﬂuorescent cells was calculated.INHIBITION OF THE ACTIVATION OF ERK1/2For the ERK inhibition study, the MAP/ERK inhibitor PD98059 (Calibio-
chem, San Diego, CA, USA)25 was used at a concentration of 25 mM.
PD98059 was added to the adherent hMSC 2 h before the chondrogenic cul-
ture. After 2 h, the medium was removed from the cultures, the cell layers
were washed with PBS, and the cells were detached by incubation with
0.25% trypsin/EDTA, counted, and induced to undergo chondrogenesis as
described above. In preliminary experiments, inhibitors were titrated at con-
centrations ranging from 10 to 50 mM and a concentration of 25 mM showed
optimal inhibition of ERK1/2 phosphorylation. Control cultures were supple-
mented with 0.0345% dimethyl sulfoxide (DMSO) alone, because the inhibi-
tors were dissolved in DMSO. Both 25 mM PD98059 or 0.0345% DMSO
alone showed no signiﬁcant difference in their growth-inhibitory or cytotoxic
effects on hMSCs as evaluated by tetrazolium assay (MTT) (data not shown).PROTEIN ISOLATION AND WESTERN BLOT ANALYSISAggregates from different treatments and multiple time points were pro-
cessed for Western blotting. In brief, aggregates were lysed with the extrac-
tion buffer containing 50 mM Tris, 1% NP-40, 150 mM NaCl, 5 mM EDTA,
0.01 M phenylmethyl sulphonylﬂuoride (PMSF) (Sigma) and 2X phosphatase
inhibitor mixture (Pierce, Rockford, IL, USA). Proteins were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on
10% acrylamide gels and transferred to polyvinylidene ﬂuoride (PVDF) mem-
branes. After blocking, the blots were probed with the appropriate primary an-
tibody [rabbit anti-Gas7 antiserum at 1:50026, rabbit anti-ERK1/2 antiserum
(Santa Cruz Biotechnology, Santa Cruz, CA) at 1:300, rabbit anti-p-ERK an-
tiserum (Santa Cruz) at 1:300, rabbit anti-glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) antiserum (Santa Cruz) at 1:1000, and rabbit anti-GFP
antiserum (Santa Cruz) at 1:1000]. After washing, the blots were incubated
with alkaline phosphatase-conjugated goat anti-rabbit immunoglobulin G
(IgG) (1:10,000, Sigma). After washing, the blots were developed with
by BCIP (5-bromo-4-chloro-3-indolyl-phosphate) in conjunction with NBT
(nitro blue tetrazolium) (BCIP/NBT) color development substrate (Promega,
Madison, WI, USA) according to the manufacturer’s protocol.REVERSE TRANSCRIPTION (RT)-PCRThe expression level of SOX9 mRNA during the chondrogenesis of hMSCs
was evaluated with RT-PCR. Meanwhile, to additionally evaluate the Gas7
expression during the chondrogenesis of hMSCs, aggregates from multiple
timepointswere further processed forRT-PCR.Total cellularRNAwasextracted
using Trizol reagent (Invitrogen) according to themanufacturer’s protocol. Chon-
drogenic aggregate cultures were ﬁrst brieﬂy homogenized in Trizol reagent to
increase yield efﬁciency. Equal amounts of RNA samples were reverse-
transcribed byusing randomhexamers and theSuperScript First StrandSynthe-
sis System (Invitrogen). PCR ampliﬁcation of cDNA was carried out using Taq
PCD Mater Mix (Qiagen, Valencia, CA, USA) and the primer pairs for hGas7a,
forward (50-CTGGCCCAGAATATGGTGACTTAGG-30) and reverse (50-CTT
GGCAGAGAACTTGAGGTGAACTTC-30); hGas7b, forward (50-AATGAGAC-
CACCTGGGAACGTCC-30) and reverse (50-CTTGGCAGAGAACTTGAGGTG
AACTTC-30); SOX9 forward (50-CATGAGCGAGGTGCACTCC-30) and reverse
(50-TCGCTTCAGGTCAGCCTTG-30). Ampliﬁcation cycles consisted of 1 min
denaturation at 95C, 1 min annealing at 58C, 1 min polymerization at 72C,
and ﬁnally a 10 min extension at 72C. The primer pairs for GAPDH, forward
(50-GGGCTGCTTTTAACTCTGGT-30) and reverse (50-TGGCAGGTTTTTCTA-
GACGG-30), were used as a control for RNA loading of samples. PCR products
were analyzed with 1.2% agarose gel electrophoresis.INHIBITION OF SOX9For the SOX9 inhibition study, the SOX9 siRNA (Santa Cruz; a pool of four
separate strands: CGUGGAGGAUGAUGGAGAAtt; GGCAAGCAAAGGAGA
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was used at a concentration of 25 nM. Transient transfection was mediated
by Lipofectamine 2000 as described above. To assess non-speciﬁc effects
resulting from the transfection process, itself, a control siRNA (Santa Cruz)
was also used. The transfection mixture that had been added to the adherent
hMSC was replaced after 24 h with culture medium. After 12 h, the medium
was removed from the cultures, the cell layers were washed with PBS, and
the cells were detached by incubation with 0.25% trypsin/EDTA, counted,
and induced to undergo chondrogenesis as described above.QUANTIFICATION OF CHONDROGENIC CAPACITYThe chondrogenic capacities of aggregates were evaluated as the sizes of
aggregates, contents of glycosaminoglycan (GAG), and proteoglycan and
type II collagen deposition after 21 days in chondrogenic cultures. To deter-
mine the GAG content, aggregates were digested with papain27. Aliquots of
25 ml of the papain-digested extracts were mixed with 250 ml of 0.02% Safra-
nin O (Sigma). The mixtures were ﬁltered through the nitrocellulose mem-
brane with a dot blot apparatus (Bio-Rad, Hercules, CA, USA). The
individual dots were cut out from the ﬁlter, and incubated in 10% acetylpyridi-
nium chloride to solubilize the Safranin O. The absorbance of the solubilized
Safranin O was read at 536 nm and compared with that from chondroitin sul-
fate standards (Seikagaku America, Falmouth, MA, USA)23. DNA content in
the aggregates was also determined. For the determination of DNA content,
aliquots of the papain-digested extracts were combined with 0.1 N NaOH, in-
cubated at room temperature for 20 min, and neutralized with 0.1 N HCl in 5 M
NaCl, 100 mM NaH2PO4. This mixture was combined with 1 ml of 0.7 mg/ml
Hoechst 33258 (Sigma) in water. Fluorescence was read at an excitation
wavelength of 360 nm and emission wavelength of 460 nm and compared
with that from a certiﬁed calf thymus DNA standard (Sigma). Differences in
DNA content are assumed to reﬂect differences in cell number.
To additionally evaluate chondrogenesis in the aggregates, samples were
formalin-ﬁxed and parafﬁn-embedded after 21 days in chondrogenic culture.
Adjacent 5 mm sections were stained for proteoglycan with Safranin O stain-
ing or for type II collagen by immunohistochemistry with antibody to type II
collagen (Developmental Studies Hybridoma Bank, Cat# II-II6B3). Sections
were examined by microscopy (200-fold magniﬁcation, Olympus, Japan)
and recorded with a SPOT-RT digital camera.STATISTICAL ANALYSISEach continual variable was analyzed for statistical signiﬁcance by
Student’s t test with a conﬁdence level of 95% (P< 0.05). All values are
reported as mean standard deviation (SD).Fig. 1. The expression of hGas7 during chondrogenic differentiation of h
gregates of hMSCs cultured in chondrogenic condition. The extract prote
were immunoblotted with anti-Gas7 antiserum. Probing for GAPDH of th
mouse brain and 293 cells transiently expressing cloned Gas7 cDNAs w
with (*) in third and ﬁfth day samples. Besides Gas7a and Gas7b protei
transfected 293 cells probably resulted by alternative translation11. (B) T
of hMSCs cultured in chondrogenic condition. Agarose gel electrophores
positive control. The ﬁgure shows the results of a representativeResultsEXPRESSION OF hGas7 IS REQUIRED FOR THE
CHONDROGENIC DIFFERENTIATION OF hMSCsBM-derived hMSC aggregates treated with and without
TGF-b1 were assayed for hGas7 activity. As determined
by Western blot, hGas7b was up-regulated at day 3 follow-
ing TGF-b1 treatment, reached a peak at day 5, and then
decreased [Fig. 1(A)]. Unlike hGas7b, hGas7a was
extremely faint or absent in hMSCs with or without TGF-b1
treatment. Similar transient expression of hGas7b was
detected by RT-PCR at day 2 and day 3 following TGF-b1
treatment [Fig. 1(B)]. Without TGF-b1 treatment, the expres-
sion of hGas7b was not detected in control aggregate
cultures by Western blot and RT-PCR analyses (data not
shown).
To assess whether hGas7 is necessary for hMSC chon-
drogenic differentiation, hGas7a and hGas7b antisense oli-
gonucleotides (hGas7a-As and hGas7b-As) were used to
inhibit the expression of hGas7 during hMSC chondrogenic
differentiation. hGas7b-As was able to suppress the expres-
sion of hGas7b in chondrogenic aggregate cultures of
hMSCs, but this suppression was not observed for hMSCs
treated with hGas7a-As or in control cultures [Fig. 2(A)]. By
several criteria, interference with hGas7b production
caused adverse effects on the chondrogenic differentiation
of hMSCs [Fig. 2(BeE)]. After 21 days of chondrogenic cul-
tures, hMSCs treated with hGas7b-As formed aggregates
that were signiﬁcantly smaller than the aggregates made
with cells expanded in the presence of hGas7a-As or under
control conditions [P< 0.05, Fig. 2(B and C)]. Analysis of
the DNA content of the aggregates demonstrated no signif-
icant differences between the groups in the amount of DNA
per aggregate at the time points analyzed [Fig. 2(D), left]. In
contrast, analysis of the GAG content revealed that aggre-
gates made with cells expanded in the presence of hGas7-
As contained signiﬁcantly less GAG, both per aggregateMSCs. (A) Proteins were extracted in multiple time points from ag-
ins were analyzed on Western blots. Aliquots of 40 mg of proteins
e same blot was also performed as the loading control. Extracts of
ere used as positive controls. Expected Gas7b protein is indicated
ns, unexpected small proteins were also detected in hGas7 cDNA
otal RNAs were extracted in multiple time points from aggregates
is of RT-PCR products was analyzed. hGas7 cDNA was used as
experiment from three experiments with different samples.
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[Fig. 2(D), right].
The extent of chondrogenesis was further assessed by
histology after Safranin O staining for proteoglycan deposi-
tion and by immunohistochemistry for type II collagen depo-
sition. Histological and immunohistochemical observations
revealed that proteoglycan and type II collagen deposition
was detected throughout the entire extracellular matrix of
aggregates made with cells expanded in the control and
hGas7a-As group, except for the peripheral layersFig. 2. Interference with hGas7 production delays chondrogenic differenti
gregates made with hMSCs pre-treated with Lipofectamine 2000 (contro
sense oligonucleotide (hGas7b-As) and cultured under chondrogenic con
with anti-Gas7 antiserum. Probing of the same blot for GAPDH was used
protein was used as the positive control. Molecular weight markers are in
different treatments and cultured under chondrogenic conditions for 21 day
(E) proteoglycan (Safranin O) and type II collagen deposition. In (E), nuc
content of ﬁve replicate aggregates are shown as mean and SD, *signiﬁca
bar¼ 500 mm; (D) bar¼ 100 mm. The ﬁgure shows the results of a repres[Fig. 2(E)]. In contrast, these molecules were detected in
only a portion of the extracellular matrix of pellets made
with cells expanded in the presence of hGas7b antisense
oligonucleotide [Fig. 2(E)].OVEREXPRESSION OF hGas7 IS NOT SUFFICIENT FOR
CHONDROGENIC DIFFERENTIATION OF hMSCsTo further clarify the role of hGas7 in chondrogenic differ-
entiation, the human full length Gas7 protein wasation of hMSCs. (A) Aliquots of 40 mg of proteins extracted from ag-
l), hGas7a antisense oligonucleotide (hGas7a-As), or hGas7b anti-
ditions for 5 days were extracted and analyzed by Western blotting
as the loading control. An extract of mouse brain protein of mouse
dicated at right. (BeE) The chondrogenic capacities of hMSCs with
s were measured as (B,C) size of aggregates, (D) GAG content and
lei were counter-stained with DAPI (DAPI). (C) Sizes and (D) GAG
nt decrease compared to control group (P< 0.05). Magniﬁcation: (B)
entative experiment from three experiments with different samples.
Fig. 2 (continued).
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combinant plasmid DNA (hGas7aeEGFP or hGas7be
EGFP) containing the coding sequence for EGFP. The trans-
fection efﬁciencies were 28 2.3%, 32 3.4%, and
35 4.3% for EGFP, hGas7aeEGFP, and hGas7beEGFP,
respectively [a representative cell image shown in
Fig. 3(A)]. Overexpressed proteins were mainly located
in cytoplasm of transfected hMSCs (data not shown).
The predicted sizes of proteins were detected in extracts
of the hMSCs transfected with EGFP (25 kDa), hGas7be
EGFP (70 kDa), and hGas7aeEGFP (58 kDa) plasmids
[Fig. 3(B)].
To further conﬁrm the overexpression of plasmid and in-
hibitory function of Gas7 antisense oligonucleotides in pellet
culture system, hMSCs pre-treated without or with hGas7
speciﬁc antisense oligonucleotides were transfected with
EGFP, hGas7aeEGFP, or hGas7beEGFP plasmid and
cultured under chondrogenic condition. Overexpression of
Gas7 was shown to be inhibited by speciﬁc antisense oligo-
nucleotides [Fig. 3(B)].
Without the following treatment of TGF-b1, hMSCs, trans-
fected with or without EGFP, hGas7aeEGFP, or hGas7be
EGFP, were unable to form chondrogenic aggregates as
measured by aggregate size [Fig. 4(A and B)], GAG content
[Fig. 4(C)], and proteoglycan and type II collagen deposition
[Fig. 4(D)]. Furthermore, with the following treatment of
TGF-b1, there was no difference of chondrogenic capacity
of hMSCs, transfected with EGFP, hGas7aeEGFP, or
hGas7beEGFP (data not shown).INHIBITION OF ERK1/2 ACTIVATION OR SOX9 PARTIALLY
INHIBITED Gas7 AMPLIFICATION IN CHONDROGENESISBM-derived hMSC aggregates treated with and without
TGF-b1 were assayed for the time course of activation of
ERK1/2 and the expression of SOX9. As determined by
Western blot, the addition of TGF-b1 led to the rapid tran-
sient phosphorylation of ERK (p-ERK) which increased dra-
matically at 0.5 h and was maintained until 2 h, after which
p-ERK was decreased at 4 h and returned to basal levels at
day 1 [Fig. 5(A), up]. However, the total ERK1/2 did not
change during the chondrogenic culture period. Activation
of ERK1/2 was not detected in untreated control aggregate
cultures [Fig. 5(A), low].
PD98059, a selective inhibitor of ERKemitogen-activated
protein kinasekinase (MEK)1, was used to suppress the ac-
tivation of ERK1/2. PD98059 at 25 mM was able to suppress
the generation of p-ERK, but did not affect the protein levels
of ERK1/2 [Fig. 5(B)]. Inhibition of the activation of ERK1/2
with PD98059 blocked the expression of hGas7b in chon-
drogenic cultures of hMSCs [Fig. 5(C)]. PD98059 did not
elicit detectable effects on hGas7a in chondrogenic cul-
tures, which could be due to the extremely low levels or ab-
sence of hGas7a in the cells (data not shown). In contrast,
inhibition of hGas7b did not prevent the phosphorylation of
ERK1/2 [Fig. 5(D)].
As determined by RT-PCR, the addition of TGF-b1 led to
an up-regulation of SOX9 which increased dramatically at
2 h and was maintained until day 2, after which SOX9
was decreased at day 3 and returned to basal levels at
Fig. 3. Overexpression of hGas7 during chondrogenic differentiation of hMSCs. (A) Phase contrast (left) and ﬂuorescence (right) microscopic
view of Lipofectamine 2000 mediated hGas7beEGFP transfer into hMSC. Scale bars indicate 200 mm. (B) hMSCs pre-treated without (EGFP,
a, b) or with (As-a, As-b) hGas7 speciﬁc antisense oligonucleotides were transfected with EGFP, hGas7aeEGFP (a, As-a), or hGas7beEGFP
(b, AS-b) plasmid and cultured under chondrogenic condition for 5 days. Proteins in pellets made with hMSCs with different treatments were
extracted and analyzed by Western blotting. hMSCs pre-treated with Lipofectamine 2000 only were used as control (control). Aliquots of 40 mg
of protein were immunoblotted with anti-GFP antiserum. GAPDH was used as the loading control. Molecular weight markers are indicated at
right. The ﬁgure shows the results of a representative experiment from three experiments with different samples.
1408 Y. Chang et al.: Involvement of Gas7 in chondrogenesis of hMSCsday 21 [Fig. 6(A)]. Up-regulation of SOX9 was not detected
in untreated control aggregate cultures (data not shown).
SOX9 siRNA was used to suppress the up-regulation of
SOX9 [Fig. 6(B)]. Inhibition of SOX9 partially blocked the
expression of hGas7b in chondrogenic cultures of hMSCs
[Fig. 6(C)]. In contrast, inhibition of hGas7b did not prevent
the up-regulation of SOX9 [Fig. 6(D)]. Inhibition of the
activation of ERK1/2 or interfering of the expression of
SOX9 both caused adverse effects on the chondrogenic
differentiation of hMSCs (data not shown), similar to the
effects produced by inhibition of the expression of hGas7b
(Fig. 2).Discussion
BM-derived hMSCs serve as a useful model for the inves-
tigation of mechanisms responsible for the generation,
development, and regeneration of cartilage tissue12,13,20.
By using this model system in this study, we found that
the hGas7b was dramatically and transiently induced by
TGF-b1 in the hMSC aggregate culture system. Reduction
in the level of expression of hGas7b with speciﬁc antisenseoligonucleotides interfered with chondrogenic differentiation
of hMSCs, indicating that hGas7 is required for chondro-
genesis. Although hGas7a was demonstrated to be impor-
tant in the development of neuronal cell processes4,11, it
was undetected in hMSCs. It is, therefore, not surprising
that treatment of hMSCs with hGas7a-speciﬁc antisense
oligonucleotide did not affect chondrogenic capacity. The
data also suggest that hGas7a and hGas7b may have dif-
ferent functional role. However, without TGF-b1 treatment,
overproduction of hGas7 with either hGas7aeEGFP or
hGas7beEGFP plasmid in hMSCs was unable to induce
chondrogenesis of hMSCs. Nevertheless, with TGF-b1
treatment, hGas7eEGFP overexpression still did not
improve chondrogenesis of hMSCs, as did overexpression
of EGFP. These results suggest that Gas7 alone is not
sufﬁcient to induce or promote chondrogenesis. Since
Gas7eEGFP fusion protein, like Gas7, is capable of regu-
lating the development of cell processes11, the inability of
hGas7eEGFP to modulate chondrogenesis is unlikely due
to interference by EGFP. Transfection of viral vector or
non-viral EGFP plasmid has been demonstrated to be with-
out inﬂuence on the differentiation capacity of hMSCs both
in vitro and in vivo28,29.
Fig. 4. Overexpression of hGas7 is not sufﬁcient to induce chondrogenic differentiation of hMSCs. The chondrogenic capacities of hMSCs
pre-treated with Lipofectamine 2000 (control) or transfected with EGFP (EGFP), hGas7aeEGFP (a), or hGas7beEGFP (b) plasmids and
cultured in incomplete chondrogenic medium [TGF-b1()] for 21 days were measured as (A,B) size of aggregates, (C) GAG content and
(D) proteoglycan (Safranin O) and type II collagen deposition. In (D) nuclei were counter-stained with 40,6-diamidino-2-phenylindole
(DAPI). (B) Size and (C) GAG content of ﬁve replicate pellets are shown as mean and SD. The hMSCs pre-treated with Lipofectamine
2000 (control) cultured in complete chondrogenic medium [TGF-b1(þ)] was used as positive control. Magniﬁcation: (A) bar¼ 500 mm, (D)
bar¼ 100 mm. The ﬁgure shows the results of a representative experiment from three experiments with different samples.
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Fig. 5. Expression and phosphorylation of ERK1/2 during
chondrogenic differentiation of hMSCs. (A) Proteins extracted
from aggregates at multiple time points during the hMSCs chondro-
genic process were analyzed by Western blotting. Aliquots of 40 mg
of cell extracts were immunoblotted with anti-p-ERK antibody (p-
ERK) and anti-ERK1/2 antibody (ERK1/2). (B,C) Proteins extracted
from aggregates made with hMSCs pre-treated without (control) or
with 25 mM PD98059 and cultured under chondrogenic conditions
for 0.5 h (B) or 5 days (C) were extracted and analyzed by Western
blotting. Aliquots of 40 mg of cell extracts were immunoblotted with
(B) anti-ERK1/2 antibody (ERK1/2), anti-p-ERK antibody (p-ERK)
and (C) anti-Gas7 antiserum. (D) Proteins extracted from aggre-
gates made with hMSCs pre-treated with Lipofectamine 2000
(control), hGas7a antisense oligonucleotide (hGas7a-As), or
hGas7b antisense oligonucleotide (hGas7b-As) and cultured under
chondrogenic conditions for 0.5 h were extracted and analyzed by
Western blotting. Aliquots of 40 mg of cell extracts were immuno-
blotted with anti-p-ERK antibody (p-ERK) and anti-ERK1/2 antibody
(ERK1/2). (AeD) Probing of the same blot for GAPDH was used as
the loading control. Molecular weight markers are indicated at right.
The ﬁgure shows the results of a representative experiment from
three experiments with different samples.
Fig. 6. Expression SOX9 during chondrogenic differentiation of
hMSCs. (A) Total RNAs were extracted in multiple time points
from aggregates of hMSCs cultured in complete chondrogenic me-
dium. Agarose gel electrophoresis of RT-PCR products was ana-
lyzed. (B,C) Total RNAs extracted from aggregates made with
hMSCs pre-treated with Lipofectamine 2000 (control), control
siRNA or with SOX9 siRNA and cultured under chondrogenic con-
ditions for 2 h (B) or 2 days (C) were extracted and analyzed by
agarose gel electrophoresis of RT-PCR products. (D) Total RNAs
extracted from aggregates made with hMSCs pre-treated with Lip-
ofectamine 2000 (control), hGas7a antisense oligonucleotide (a), or
hGas7b antisense oligonucleotide (b) and cultured under chondro-
genic conditions for 2 h were extracted and analyzed by agarose
gel electrophoresis of RT-PCR products. GAPDH was used as
the loading control. The ﬁgure shows the results of a representative
experiment from three experiments with different samples.
1410 Y. Chang et al.: Involvement of Gas7 in chondrogenesis of hMSCsMoreover, we found that ERK1/2 and SOX9 are either
activated or up-regulated before Gas7 induction during
chondrogenic differentiation of hMSCs. The expression of
hGas7b could be partially suppressed by interfering the
activation of ERK1/2 with PD98059, a selective inhibitor of
MAP kinase kinase25,30 or by inhibition of the up-regulation
of SOX9 with SOX9 siRNA. Based on the literature report20,
the gene expression of the transcription factor SOX9, a crit-
ically important transcriptional regulator of cartilage-speciﬁc
genes and a potent inducer of the chondrocytic phenotype,
is regulated by MAP kinase signaling in chondrogenesis20.
Taken these together, the results suggest that the transient
expression of hGas7, especially hGas7b, is necessary for
TGF-b1-induced chondrogenesis of hMSCs, which is down-
stream of ERK1/2-SOX9 along the pathway.
Changes in cell morphology have been extensively stud-
ied, mainly because they are commonly correlated with
mammalian cell differentiation and known to affect various
cellular functions such as signal transduction, gene expres-
sion, and terminal differentiation of cells31. Because the
1411Osteoarthritis and Cartilage Vol. 16, No. 11cytoskeleton determines cell shape, many of these changes
can be understood in terms of a dynamic reorganization of
the cytoskeleton. The morphological changes of hMSCs
during osteogenic differentiation in vitro have been demon-
strated to be associated with changes in cytoskeleton orga-
nization32. Disruption of the actin cytoskeleton with
cytochalasin D also is known to induce chondrogenic differ-
entiation of chick embryo limb bud mesenchymal cells33.
Gas7 has been shown to bind to F-actin and to promote ac-
tin polymerization3. These interactions are suggested to be
involved in Gas7-induced morphological changes, as dis-
ruption of the actin cytoskeleton interferes with the effects
of Gas7 on morphology during neuronal differentiation3.
Therefore, the expression of hGas7b may participate in
the reorganization process of the F-actin-based cytoskele-
ton during chondrogenic differentiation of hMSCs. This
study is the ﬁrst to present a functional role of hGas7 in
non-neuronal cells, supporting the notion that Gas7 may
have a broad spectrum of biologically important roles.
The activation of ERK1/2 has been demonstrated to par-
ticipate in the signal pathway of hMSC differentiation, both
in chondrogenesis20 and osteogenesis34. Activation of the
ERK1/2 pathway is known to disrupt the actin cytoskeleton
by overcoming the effects of constitutively activated RhoA
which regulates SOX9 expression, to organize the actin
cytoskeleton35e37. Furthermore, during chondrogenesis of
hMSCs, ERK1/2 promotes cartilage-speciﬁc gene expres-
sion and regulates the expression of N-cadherin, which is
anchored to intracellular actin20. Our data indicate that the
ERK1/2 and SOX9 functions as a positive modulator of
chondrogenic differentiation in hMSCs, consistent with pre-
vious ﬁnding20. However, studies using other cell culture
systems have implicated the ERK1/2 as an inhibitory regu-
lator of chondrocyte differentiation17,18. The opposite role of
MEKeERK signaling may relate to the different cell line or
different species.
In in vitro aggregate culture system, SOX9 was up-
regulated from early (2 h) to middle stage (14 days) of culture
period, however, SOX9 returned to basal levels in the late
stage (21 days) [Fig. 6(A)]. SOX9 has been reported to help
maintain the chondrocyte phenotype to prevent promoting
terminal differentiation. In this culture system, type X collagen
which expressed in hypertrophic chondrocyte was stained
after 21 days culture23. These results indicated the terminal
differentiation of hypertrophic chondrocyte and explained
the decrease expression of SOX9 in the late stage culturing.
In this study, we found that the hGas7b was dramatically and
transiently induced by TGF-b1 in the hMSC aggregate culture
system, but we did not know the up-regulation of hGas7 has
any effects on the promotion or prevention of terminal differ-
entiation of chondrocyte. Although it is not known whether
hGas7 directly or physically interacts with ERK1/2eSOX9,
functional link between them in chondrogenesis, at least in
hMSC culture system, is strongly suggested.
In this study, we showed that expression of hGas7b is po-
tentially regulated by activation of ERK1/2 and the expression
of SOX9, which are required for hMSC chondrogenesis.
Taken together, these results suggest that involvement of
hGas7b in chondrogenic differentiation of hMSCs may be
via an ERK1/2eSOX9 pathway-regulated cytoskeletal
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